Banced Corp lowered its stake in Baxter International Inc. (NYSE:BAX) by 2.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,044 shares of the company’s stock after selling 181 shares during the period. Banced Corp’s holdings in Baxter International were worth $307,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BAX. Meag Munich Ergo Kapitalanlagegesellschaft increased its stake in shares of Baxter International by 33.9% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 7,900 shares of the company’s stock valued at $248,000 after buying an additional 2,000 shares during the period. J. Goldman & Company acquired a new stake in Baxter International during the third quarter valued at about $3,121,000. ING Groep increased its stake in Baxter International by 24.9% in the third quarter. ING Groep now owns 804,935 shares of the company’s stock valued at $26,434,000 after buying an additional 160,664 shares during the last quarter. Searle & Company increased its stake in Baxter International by 5.0% in the fourth quarter. Searle & Company now owns 31,600 shares of the company’s stock valued at $1,175,000 after buying an additional 1,500 shares during the last quarter. Finally, Northcoast Asset Management increased its stake in Baxter International by 5.7% in the third quarter. Northcoast Asset Management now owns 42,775 shares of the company’s stock valued at $1,405,000 after buying an additional 2,297 shares during the last quarter.

Shares of Baxter International Inc. (NYSE:BAX) traded up 1.36% during midday trading on Tuesday, reaching $36.54. The company had a trading volume of 2,262,784 shares. Baxter International Inc. has a 12-month low of $32.18 and a 12-month high of $43.44. The firm has a market capitalization of $19.99 billion and a price-to-earnings ratio of 11.64. The company has a 50 day moving average of $36.78 and a 200 day moving average of $37.04.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.12. The firm earned $2.49 billion during the quarter, compared to the consensus estimate of $2.46 billion. Baxter International’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.35 EPS. Analysts anticipate that Baxter International Inc. will post $1.25 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, January 4th. Shareholders of record on Friday, December 4th were issued a $0.115 dividend. The ex-dividend date of this dividend was Wednesday, December 2nd. This represents a $0.46 dividend on an annualized basis and a yield of 1.26%.

Several research firms recently issued reports on BAX. Zacks Investment Research downgraded shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, January 12th. Piper Jaffray reduced their price target on shares of Baxter International from $90.00 to $39.00 and set an “overweight” rating for the company in a research report on Monday, November 16th. Goldman Sachs lifted their price target on shares of Baxter International to $43.00 in a research report on Friday, November 13th. Leerink Swann reissued a “market perform” rating and issued a $42.00 price target on shares of Baxter International in a research report on Wednesday, October 28th. Finally, Cowen and Company reduced their price target on shares of Baxter International from $74.00 to $38.00 in a research report on Wednesday, October 28th. Ten investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $41.83.

Baxter International Inc. (NYSE:BAX) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

12 Month Chart for NYSE:BAX

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.